Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab in migraine with comorbid MDD
NCT04041284Phase 4Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2019
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 4 trial of fremanezumab in migraine, sponsored by Teva Pharmaceutical Industries Ltd.. Started Sep 2019; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04041284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041284.